Sanofi Makes $480 Million Push to Stay Competitive in Vaccines
Photographer: Joel Saget/AFP/Getty Images
This article is for subscribers only.
Sanofi will invest 400 million euros ($477 million) a year in messenger-RNA technology to give it an edge in treating infectious diseases beyond Covid-19.
The French drugmaker is bringing together about 400 workers from Massachusetts and France as part of an mRNA “center of excellence” focused on everything from basic research to manufacturing, it said in a statement Tuesday.